EVAXION_DEEPBLUE_RGB.png
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
02 déc. 2024 08h00 HE | Evaxion Biotech
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...
EVAXION_DEEPBLUE_RGB.png
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
03 oct. 2024 08h00 HE | Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
AgTech_Breakthrough_Awards_Logo.png
Edete Precision Technologies Wins 2024 AgTech Breakthrough Award For “AgTech Implementation of the Year”
21 août 2024 08h00 HE | AgTech Breakthrough
LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) -- AgTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global agricultural...
RM Primary Logo - Humble.png
Revolution Medicines Completes Acquisition of EQRx
09 nov. 2023 09h10 HE | Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
BioTech Breakthrough Awards Badge[1] copy.jpg
HistoSonics Edison System Recognized With BioTech Breakthrough Award For “MedTech Innovation Of The Year”
08 nov. 2023 08h02 HE | BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
RM Primary Logo - Humble.png
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
06 nov. 2023 16h05 HE | Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
RevolutionLogo.png
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
22 oct. 2023 02h30 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
cmi_logo.png
[Latest] Global Precision Fermentation Market Size/Share Worth USD 25.54 Billion by 2032 at a 45% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
09 oct. 2023 18h30 HE | Custom Market Insights
Austin, TX, USA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Precision Fermentation Market Size, Trends and Insights By Ingredient (Whey...
RevolutionLogo.png
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
19 sept. 2023 07h00 HE | Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
RevolutionLogo.png
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
17 août 2023 16h05 HE | Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...